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Effect of the Dysbindin Gene on Antimanic Agents 
in Patients with Bipolar I Disorder 
 
 
 
ObjectiveᄏWe previously reported an association between dysbindin gene (DTNBP1) 
variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting 
that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. 
MethodsᄏA total of 45 BID patients were treated with antimanic agents (lithium, valproate, 
or carbamazepine) for an average of 36.52 (±19.87) days. After treatment, the patients 
were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating 
Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, 
rs2005976 G/A, rs760761 C/T and rs2619522 A/C).  
ResultsᄏThere was no association between the variants investigated and response to mood 
stabilizer treatment, even after considering possible stratification factors. 
ConclusionᄏAlthough the small number of subjects is an important limitation in our study, 
DTNBP1 does not seem to be involved in acute antimanic efficacy. 
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Introduction 
 
Bipolar disorder is known to be affected by genetic factors.
1-3 Although it is not a 
classical neurodegenerative disease, bipolar disorder has been recently reported to be
associated with a neurodegenerative pathophysiology.
4 Moreover, cell-life promoting
events are reasonably responsible for neuronal plasticity and resilience, which have
been recognized as relevant factors in the development of bipolar disorder.
5 Therefore, 
the dysbindin seems to be a good candidate as it is associated with both intracellular
trafficking and signal transduction.
6,7 
Lithium, valproate and carbamazepine have been considered as the first line treat-
ments for both the acute and long-term treatment of patients with bipolar disorder.
8
Given the paucity of the clinical predictors of response,
9 pharmacogenetic predictors 
would be of great assistance to clinicians. The mood-stabilizing, prophylactic, and neu-
roprotective effects of lithium in association with variations of numerous genes have
been reported in genome-wide studies.
10-12  
However, carbamazepine and valproate have not been as widely investigated as
lithium. Nevertheless, their prophylactic activities have been associated with some
genes or proteins,
13,14 providing some rationale for a pharmacogenetic approach to
investigating their acute antimanic effects. This field of research is particularly diffi-
cult and intriguing since the specific mechanism of action leading to mood stability
has yet to be identified
14,15 and because the genetic inheritance of acute antimanic res-
ponse remains unclear. Even though the prophylactic action of mood stabilizers has
been widely investigated, pharmacogenetic studies investigating the acute antimanic
effect of mood stabilizers are lacking.  
 
 
 
 
DH Yun et al. 
www.psychiatryinvestigation.org 103 
Therefore, our group used a pharmacogenetic appro-
ach to investigate the possibility that dysbindin gene has 
any effects on response to antimanic agents. A portion 
of the coding sequence for dysbindin gene (rs3213207; 
rs1011313; rs760761; rs16876759; rs2619522) was cho-
sen on the basis of evidence of an association between 
dysbindin and depressive spectrum disorders, bipolar dis-
order and schizophrenia.
16-19 Genetic investigations were 
performed on Korean patients with bipolar disorder. 
 
Methods 
 
Subjects 
The subjects were 45 inpatients (20 males) who had 
been diagnosed with Bipolar I Disorder (BID) and scored 
at least 13 on the Young Mania Rating Scale (YMRS) 
at baseline. The clinical diagnosis was confirmed by the 
consensus of two board-certified psychiatrists based on 
Diagnostic and Statistical Manual of Mental Disorders 
IV (DSM-IV) criteria,
20 and patients with comorbid Axis 
I disorders other than BID were excluded. Subjects with 
neurological and current medico-surgical illnesses were 
also excluded. Patients were administered the Clinical 
Global Impression (CGI) scale and the YMRS at admi-
ssion. The patients were assessed for the retest sessions 
just before their discharge following the cessation of the 
manic symptoms.   
All subjects were biologically unrelated, native Korean 
descendants currently residing in Korea. Written informed 
consent was provided by the subjects after the purpose 
and method of the study had been explained. The insti-
tutional review board of The Catholic University of Korea, 
Kangnam St. Mary’s Hospital approved the study, which 
was conducted in accordance with the Declaration of 
Helsinki. 
 
Genetic analyses 
The dysbindin gene, DTNBP1, was initially cloned by 
Benson and colleagues.
6 It is located at position 6p 24-2 
and has three known isoforms: A, B and C. Isoforms A and 
C have 10 exons spanning approximately 140 kb, while 
isoform B has 10 exons spanning approximately 139 kb. 
Genomic DNA was extracted from blood by standard 
methods and then quantified. The high-throughput geno-
typing method using pyrosequencer (Biotage AB, Sweden) 
was used to genotype 5 single nucleotide polymorphisms 
(SNPs) (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, 
rs760761 C/T and rs2619522 A/C) of the dysbindin gene. 
Genetic variants were selected from a public database 
(National Center for Biotechnology Information, dbSNP, 
http://www.ncbi.nlm.nih.gov/SNP/).  
Polymerase chain reaction (PCR) primers (Bioneer, 
Daejeon, Korea) and sequencing primers (Bioneer, Dae-
jeon, Korea) used for the pyrosequencing assay were 
designed using the Pyrosequencing Assay Design Soft-
ware v1 (Biotage AB, Sweden), and one primer from 
each primer set was biotinylated. 
 
Statistical analyses 
Haploview 3.2 was used to generate a linkage disequi-
librium map and to test for Hardy-Weinberg equilibrium. 
Single genotype associations with YMRS and CGI scores 
were analyzed by analysis of variance (ANOVA). When 
including covariates or other factors, analysis of covari-
ance (ANCOVA) and multivariate analysis of co-/variance 
(MANOVA/MANCOVA) were employed. Baseline scores 
were included as covariates in addition to the clinical 
variables associated with genotypes. Comparisons with 
other clinical variables in the sample were performed 
using ANOVA or the Chi-square test. The “R” software 
(“A Programming Environment for Data Analysis and 
Graphics” Version 2.2.1) was used to analyze the haplo-
types with both discrete and continuous traits and to 
include covariates. Permutation (50,000 permutations) 
was used to estimate the global significance of the re-
sults of the haplotype analyses in order to confirm the 
expectation-maximization values. Results were consid-
ered significant with an alpha level lower than 0.05. 
With this level of significance (alpha=0.05), for sin-
gle marker allele analyses, we had a power of 0.80 to 
detect a medium-large effect size of d=0.97, which cor-
responded to a difference of approximately 4.5% in YMRS 
improvement between the two main genotype variants and 
corresponded to an explained variance of about 19.6%. 
 
Results 
 
The clinical characteristics of the patients are presented 
in Table 1. A significant reduction in YMRS mean score 
was reported (64.20±4.55) for the whole sample. Sub-
jects treated with lithium, valproate and carbamazepine 
had 64.94 (±4.71), 64.15 (±2.84) and 60.71 (±5.83) 
reductions in YMRS scores, respectively. The present 
study was not designed to investigate the different effi-
cacies of the single drugs, so we did not perform any 
statistical investigation in that direction. 
In the clinical correlation analysis, we observed a sig-
nificant positive correlation (R Spearman=0.63, p< 
0.0001) between YMRS scores at baseline and the % re-
duction in YMRS score by the end of treatment. We also 
observed an inverse association with age at onset and 
the % reduction in YMRS score (R Spearman=-0.29, 
p=0.05). When considering the dichotomic variable, the 
results of the “remitters” and “non remitters” were similar.  
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In regards to the genetic analysis of the dysbindin se-
quence, all markers were in Hardy-Weinberg equilibrium 
(rs3213207 p=0.94; rs1011313 p=0.55; rs760761 p= 
0.44, rs16876759 p=0.44, rs2619522 p=0.39). 
The DTNBP1 variations were not associated with the 
clinical variables of the sample or with the acute anti-
manic effects of lithium, valproate and carbamazepine. 
In addition, no association was observed when possible 
stratification factors were included in the analysis (age 
at onset, kind of drug, period of administration, admin-
istered doses, YMRS at baseline, CGI at baseline). Ha-
plotype analyses showed no significant association with 
the effect of acute antimanic treatment. Haplotypes were 
not associated with baseline YMRS (global p=0.78). 
Analysis of covariance for age and baseline scores also 
showed that the haplotypes were not associated with fi-
nal YMRS (global p=0.57) scores. 
Discussion 
 
In the present study, we did not find an association 
between the variations within the investigated DTNBP1 
coding sequence variants and the acute antimanic effects 
of lithium, valproate and carbamazepine. Minor clinically 
significant results were obtained: there was a significant 
positive correlation between baseline YMRS score and 
YMRS % score reduction by the end of treatment. We 
also observed an inverse association between age at onset 
and reduction in YMRS % score.   
Nevertheless, DTNBP1 can still be considered as a 
promising candidate for acute antimanic effects, as there 
is some evidence that dysbindin modulation in the glu-
tamatergic and GABAergic systems is related to the 
neurotransmitter imbalance associated with acute manic 
symptoms,
5,15,21 and that some antiglutamatergic agents, 
such as riluzole and lamotrigine, have antidepressant 
effects.
22  
Moreover, it has been suggested that drugs that re-
duce glutamatergic activity or glutamate receptor-related 
signal transduction may also have antimanic effects.
23 
Finally, GABAergic tone has been associated with bi-
polar disorder and its treatment.
24 DTNBP1 variants have 
been consistently associated with bipolar disorder,
25 and 
we reported that some DTNBP1 variants are signifi-
cantly associated with the response of antidepressants.
18 
In contrast, Raybould et al.
26 reported that dysbindin 
gene variants were not associated with bipolar disorder, 
and Zill et al.
27 reported that variations in the DTNBP1 
gene had no effect on the etiology of major depression 
or on the response to antidepressant treatment, which is 
in agreement with the finding of the present study. No-
netheless, further investigation into the DTNBP1 gene is 
warranted. 
The negative result presented in this paper may have 
resulted from several limitations, including the small 
sample size, heterogeneity, various durations of treat-
ment and different doses of drugs. Drug plasma level 
might be an important missing variable. The lack of ge-
nomic control to exclude stratification bias may be an-
other limitation of the study; however, the Korean pop-
ulation is considered to be genetically homogenous. 
Considering the short duration of treatment with anti-
manic agents in this study (36.5±19.9), the association 
between the DTNBP1 gene and the effects of antimanic 
drugs on the long-term treatment of bipolar I disorder 
should be confirmed.   
Finally, we investigated only a portion of the DTNBP1 
coding sequence, on the basis of evidence in the above-
mentioned literature. 
In conclusion, there was no association between genetic 
TABLE 1. Clinical characteristics of subjects with bipolar I disorder
Variables Results 
Sex (number and frequency)  
M 20  (44.4%) 
F 25  (55.6%) 
Age (years)  0032.7±010.9 
Age of onset (years)  0026.7±010.0 
Treatment drug (number and frequency 
of subjects in treatment with one drug) 
Lithium  30 (66%) 
Valproate  09 (20%) 
Carbamazepine  03 (06%) 
Other  03 (06%) 
Duration of treatment (days)  0036.5±019.9 
Treatment dose (mg/day)  
Lithium  1066.7±174.9 
Valproate  1166.7±251.2 
Carbamazepine  0600.0±200.0 
Suicide attempter (number of 
 suicide  attempters) 
3/45 attempted 
 
Psychotic features (number of   
subjects with psychotic features) 
Yes  21 (46.6%) 
No  21 (46.6%) 
Missing values  3 
CGI scores   
At baseline  05.15±00.67 
At retest  03.71±01.21 
% reduction  28.40±20.58 
YMRS scores   
At baseline  42.91±04.00 
At retest  15.24±01.47 
% reduction  64.20±04.55 
CGI: Clinical Global Impression, YMRS: Young Mania Rating Scale 
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variations in the DTNBP1 coding sequence and the acute 
antimanic effects of lithium, valproate and carbamaze-
pine in the present study. Further research with a larger 
sample is needed to confirm the role of DTNBP1 in the 
effects of antimanic drugs in patients with BID. 
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